Wells Fargo lowered the firm’s price target on Calumet (CLMT) to $28 from $29 and keeps an Overweight rating on the shares. The firm says that the small change inadequately reflects multiple adjustments, including much lower debt costs, higher multiple on Performance Brands, clear line of sight to SAF expansion and even MRL monetization.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Calumet downgraded to Hold from Buy at TD Cowen
- Calumet Specialty Products’ Forum Selection Clause: Legal and Financial Risks Unveiled
- Calumet’s Earnings Call: Strategic Wins Amid Market Challenges
- Calumet Specialty Products Reports 2024 Financial Results
- Lubrication Engineers to acquire Industrial Brands & Products of Royal Purple